Sponsor · clinical trials

Institut de Recherches Internationales Servier clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France, Spain, Japan, Germany, Italy, Netherlands, Australia, Brazil, Austria, China, Canada, Israel, Denmark, Poland, Czechia, South Korea, Ireland, Sweden, Portugal, Mexico, Taiwan and Switzerland registers with Institut de Recherches Internationales Servier as lead sponsor. Synced 10 Nov 2026

11Current trials

4Recruiting now

19Drugs in these trials

22Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Institut de Recherches Internationales Servier is the lead sponsor of 11 current clinical trials in our France, Spain, Japan, Germany, Italy, Netherlands, Australia, Brazil, Austria, China, Canada, Israel, Denmark, Poland, Czechia, South Korea, Ireland, Sweden, Portugal, Mexico, Taiwan and Switzerland registers. 4 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Ivosidenib, Azacitidine and Gemcitabine. The most-studied condition is Untreated AML.

ClinicalTrials.gov trials by status

Recruiting436%
Active, closed764%

Trials by phase

Phase 3436%
Phase 1/2436%
Phase 1327%

Clinical trials sponsored by Institut de Recherches Internationales Servier

11 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation NCT06465953 · ClinicalTrials.gov ↗ · Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS) Drugs: Azacitidine, Ivosidenib	Phase 3	Recruiting	2024-12	Germany, France, Spain, Italy, Netherlands, Brazil, Japan, Australia
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis Drugs: Cetuximab, Folfox, Gemcitabine	Phase 1/2	Recruiting	2023-04	China, France, Spain, Italy, Denmark, Japan, Australia
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy NCT07227857 · ClinicalTrials.gov ↗ · Epileptic Encephalopathy	Phase 1/2	Recruiting	2025-11	France, Spain, Italy, Japan
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation NCT02074839 · ClinicalTrials.gov ↗ · Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Drug: Ivosidenib	Phase 1	Recruiting	2014-03	France
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation NCT03173248 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) Drugs: Azacitidine, Ivosidenib	Phase 3	Active, closed	2017-06	China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. NCT03869892 · Metastatic Colorectal Cancer Drugs: Capecitabine, Trifluridine/Tipiracil	Phase 3	Active, closed	2019-03	Ireland, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Brazil, Australia
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) NCT04164901 · ClinicalTrials.gov ↗ · Grade 2 Glioma, Residual Glioma, Recurrent Glioma Drug: Vorasidenib	Phase 3	Active, closed	2020-01	Germany, France, Spain, Italy, Netherlands, Switzerland, Canada, Japan, Israel
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation NCT06501625 · ClinicalTrials.gov ↗ · Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Drugs: Cisplatin, Durvalumab, Gemcitabine	Phase 1/2	Active, closed	2024-12	Germany, France, Spain, Canada, Brazil, Japan, South Korea, Australia
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation NCT02632708 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) Drugs: Cytarabine, Daunorubicin, Enasidenib	Phase 1	Active, closed	2015-12	Germany, Netherlands
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma NCT06478212 · ClinicalTrials.gov ↗ · IDH1-mutant Glioma, IDH2-mutant Glioma Drugs: Temozolomide, Vorasidenib	Phase 1/2	Active, closed	2025-01	China, Germany, France, Spain, Italy, Netherlands, Austria, Japan, Israel
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 NCT02735083 · ClinicalTrials.gov ↗ · Advanced Lymphoid Leukemia	Phase 1	Active, closed	2021-03	France, Spain, Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Institut de Recherches Internationales Servier trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Ivosidenib5 Azacitidine2 Gemcitabine2 Vorasidenib2 Capecitabine1 Cetuximab1 Cisplatin1 Cytarabine1 Daunorubicin1 Durvalumab1 Enasidenib1 Etoposide1 Folfox1 Idarubicin1 Mitoxantrone1 Nab-paclitaxel1 Panitumumab1 Temozolomide1 Trifluridine/Tipiracil1

Conditions in Institut de Recherches Internationales Servier trials

23 conditions

Untreated AML3Newly Diagnosed Acute Myeloid Leukemia (AML)2AML Arising From Myelodysplastic Syndrome (MDS)2Metastatic Colorectal Cancer1 Leukemia, Myeloid, Acute1 Non-small Cell Lung Cancer1Histiocytic Neoplasm1Histiocytosis1BRAF Gene Mutation1IDH1-mutant Glioma1IDH2-mutant Glioma1Grade 2 Glioma1Residual Glioma1Recurrent Glioma1Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)1Myelodysplastic Syndromes (MDS)1AML Arising From Antecedent Hematologic Disorder (AHD)1Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation1Relapsed or Refractory Acute Myeloid Leukemia (AML)1Other IDH1-mutated Positive Hematologic Malignancies1Myelodysplastic Syndromes1Epileptic Encephalopathy1Advanced Lymphoid Leukemia1

By trial register

Register	Trials	Recruiting
Clinical trials in France	10	4
Clinical trials in Spain	9	3
Clinical trials in Japan	8	3
Clinical trials in Germany	7	1
Clinical trials in Italy	7	3
Clinical trials in Netherlands	6	1
Clinical trials in Australia	5	2
Clinical trials in Brazil	4	1
Clinical trials in Austria	3	0
Clinical trials in China	3	1
Clinical trials in Canada	3	0
Clinical trials in Israel	3	0
Clinical trials in Denmark	2	1
Clinical trials in Poland	2	0
Clinical trials in Czechia	2	0
Clinical trials in South Korea	2	0
Clinical trials in Ireland	1	0
Clinical trials in Sweden	1	0
Clinical trials in Portugal	1	0
Clinical trials in Mexico	1	0
Clinical trials in Taiwan	1	0
Clinical trials in Switzerland	1	0

A trial with sites in more than one country appears in each of those registers.

Questions about Institut de Recherches Internationales Servier trials

How many clinical trials does Institut de Recherches Internationales Servier sponsor?

Institut de Recherches Internationales Servier is the lead sponsor of 11 current trials on ClinicalTrials.gov in our France, Spain, Japan, Germany, Italy, Netherlands, Australia, Brazil, Austria, China, Canada, Israel, Denmark, Poland, Czechia, South Korea, Ireland, Sweden, Portugal, Mexico, Taiwan and Switzerland registers, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Institut de Recherches Internationales Servier trials recruiting?

Yes. 4 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Institut de Recherches Internationales Servier testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Ivosidenib (5), Azacitidine (2), Gemcitabine (2), Vorasidenib (2) and Capecitabine (1). The number in brackets is how many of its trials name each drug.

Does Institut de Recherches Internationales Servier have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.